Incyte (INCY) Weekend Data Points To $1B Peak Sales For Ruxolitinib - Stifel
Tweet Send to a Friend
Stifel analyst Stephen Willey reiterated a Hold rating on Incyte (NASDAQ: INCY) but believes the weekend presentation of complete results ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


